457
Participants
Start Date
April 6, 2022
Primary Completion Date
November 14, 2023
Study Completion Date
November 14, 2023
TNX-102 SL Tablet, 5.6 mg
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Placebo SL Tablet
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Tonix Clinical Site, Williamsville
Tonix Clinical Site, Charlottesville
Tonix Clinical Site, Danville
Tonix Clinical Site, Charleston
Tonix Clinical Site, Alpharetta
Tonix Clinical Site, Atlanta
Tonix Clinical Site, Jacksonville
Tonix Clinical Site, Orlando
Tonix Clinical Site, Miami Lakes
Tonix Clinical Site, Fort Myers
Tonix Clinical Site, Ocala
Tonix Clinical Site, Oldsmar
Tonix Clinical Site, Gulfport
Tonix Clinical Site, Cincinnati
Tonix Clinical Site, Evansville
Tonix Clinical Site, West Des Moines
Tonix Clinical Site, Kenosha
Tonix Clinical Site, Prairie Village
Tonix Clinical Site, New Orleans
Tonix Clinical Site, Covington
Tonix Clinical Site, Prairieville
Tonix Clinical Site, Tulsa
Tonix Clinical Site, McKinney
Tonix Clinical Site, Dallas
Tonix Clinical Site, Austin
Tonix Clinical Site, Phoenix
Tonix Clinical Site, Albuquerque
Tonix Clinical Site, Oceanside
Tonix Clinical Site, Temecula
Tonix Clinical Site, Santa Ana
Tonix Clinical Site, Portland
Tonix Clinical Site, Cromwell
Tonix Clinical Site, Boston
Tonix Pharmaceuticals, Inc.
INDUSTRY